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a b s t r a c t
Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conven-
tional eyedrops formulations. Here, we developed a controlled delivery system composed of moxiﬂoxacin-
loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-
component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospray-
ing) technique, surfactant-free moxiﬂoxacin-loaded microparticles were fabricated with diameters on the
order of 1μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to pre-
pare the microparticles for the electrospraying processing. Extended release of moxiﬂoxacin using a series
of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the
minimum inhibitory concentration (MIC). In contrast, moxiﬂoxacin loaded directly in hydrogels was released
rapidly within 24h. We observed a decrease of the drug release rate from the microparticles when using an
increased percentage of methanol in the mixed solvent from 10% to 30% (v/v), which can be explained by
the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the
microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to
localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing
in the eye.
c© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Moxiﬂoxacin (MXF) is a fourth-generation ﬂuoroquinolone with a
wide spectrum of antibacterial activities, which has been used to
treat conjunctival infections in ophthalmology [1,2]. Conventional
eyedrops show relatively poor ocular bioavailability because of the
high drainage rate of tear ﬂuid and limited contact time [3]. There-
fore, sustained and localized release of the antibiotics would improve
ophthalmic patient compliance. Various delivery vehicles have been
developed to control the release of antibiotics, including particles
[4,5], gels [6,7], and polymeric inserts [8]. However, the currently
available methods still show limited release capability or are incon-
venient for the patient, when applied directly to the eye.
Electrohydrodynamic spray drying (electrospraying) is an elec-
trostatic processing technique that has recently attracted increasing
attention [9,10]. This technique utilizes high voltage in which a por-
tion of a charged stationary liquid is ejected from the surface because
the electrical tension forces overcome the surface tension force [11].
The charged stationary liquid becomes unstable quickly and breaks
up into a mist of very ﬁne charged electrosprayed droplets. These
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droplets exhibit radii from hundreds of micrometers down to a few
nanometers, depending upon the electrospraying processing condi-
tions. When a polymer solution is applied, the solvent in the small
droplets quickly dries and the droplets, when collected, become poly-
meric particles. Unlike the double-emulsion technique [12,13], elec-
trospraying requires no surfactant and can produce drug-loaded par-
ticles simply and quickly.
Recently, we developed chondroitin sulfate-based bioadhesive
systems for medical applications [14–16]. Speciﬁcally, a chondroitin
sulfate-polyethylene glycol (CS–PEG) two-component bioadhesive
system is chosen in this study [15,16]. The ﬁrst component is chon-
droitin sulfate (CS) functionalizedwithN-hydroxysuccinimide (NHS),
i.e. chondroitin sulfate succinimidyl succinate (CS–NHS),which is able
to form amide bonds by reacting with the primary amines widely
available in human tissues. The second component employs six-arm
polyethylene glycol amine PEG–(NH2)6 as a crosslinker to provide
strong cohesive forces inside the bioadhesive hydrogel. This bioad-
hesive system (CS–PEG) has demonstrated cytocompatibility with
corneal cells and showed great potential as an ophthalmic adhesive
[15]. The ability to simultaneously deliver pharmaceuticals from this
material would enable more functionality and eliminate the need for
eyedrops.
This paper focuses on developing a moxiﬂoxacin delivery system
composed ofmoxiﬂoxacin-loadedmicroparticles encapsulated in CS–
PEG bioadhesives to achieve sustained antibiotic release and improve
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drug bioavailability for ophthalmic treatments. Microparticles were
prepared using the electrospraying technique. The CS–PEG bioadhe-
sives were applied to localize the microparticles by in situ gelling.
This unique drug-release system combines the advantages of using
microparticles to better control drug release from the hydrogel and
using bioadhesives to keep themicroparticles frombeingwashed out.
Additionally, this system allows convenient application to appropri-
ate ocular infection sites or any other sites of interest [17].
2. Materials and methods
2.1. Materials
Moxiﬂoxacin HCl was purchased from Bayer (Leverkusen, Ger-
many) and used as received. Poly(lactic-co-glycolic acid) (PLGA,
50:50, MW 40,000–75,000), dichloromethane (DCM), methanol
(MeOH), triethylamine, phosphoric acid (50%), and acetonitrile (HPLC
grade) were purchased from Sigma-Aldrich and used as received.
Chondroitin sulfate succinimidyl succinate (CS–NHS) was synthe-
sized as described previously [15,16] by reacting CS (25kDa, New
Zealand Pharmaceuticals Ltd., Palmerston North, New Zealand)
with N-(3-dimethylamino propyl)-N′-ethyl carbodiimide hydrochlo-
ride (EDC, Sigma) and N-hydroxysuccinimide (NHS, Pierce). PEG–
(NH2)6 (15.0 kDa) was purchased from Sunbio and used as re-
ceived. Dulbecco’s phosphate buffered saline (PBS, 1× ) and (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer solution
(HEPES, 1M) were purchased from Invitrogen and used as received.
2.2. Methods
2.2.1. Microparticle preparation
Moxiﬂoxacin HCl-loaded PLGAmicroparticles were fabricated us-
ing an electrospraying technique. Drug-loaded polymer solutions
were prepared containing 1.0wt% PLGA and 0.05wt% moxiﬂoxacin
HCl dissolved in one of the three different mixed solvents of MeOH/
DCM = 10:90, 20:80, and 30:70 (v/v), respectively. Each polymer so-
lution was fed into a syringe (30mL, Norm-Ject) and controlled by a
syringe pump (NE-1000, New Era Pump Systems, Inc., Farmingdale,
NY) at a ﬂow rate of 2mL/h. A needle (ﬂat tip, 22G) was connected
with the positive electrode of a high voltage supply (Gamma High
VoltageResearch, Inc., OrmondBeach, FL). A stainless steel tray (32 cm
L × 26 cmW × 6 cmH)was placed at an angle of 35◦ beside the nee-
dle with the needle pointing to the center of the tray at a distance of
15 cm. This tray was grounded and used as the particle collector. A
high voltage of 11–13kVwas used and the particleswere collected for
10h for each polymer solution. The microparticles on the plate were
further dried in air at room temperature for at least 12h. Distilledwa-
ter (40mL) was then used to collect the particles gently using a small
brush. The collected particle solutions were loaded into a centrifuge
tube (50mL) and centrifuged at 3500 rpm for 10min. After pouring
out most of the water, the precipitatedmicroparticles were vortexed,
stored in the freezer at −80 ◦C overnight, and then dried completely
using lyophilization for three days.
2.2.2. Scanning electron microscopy (SEM)
The morphology of the moxiﬂoxacin-loaded PLGA microparticles
was examined using scanning electron microscopy (ESEM, Quanta
200, FEI, Hillsboro, OR) at an accelerating voltage of 5 kV after being
coatedwith a 10nm layer of Pd. The average size and size distribution
of the microparticles were determined from 300–400 microparticles
in each condition using ImageJ (NIH 7.0.0) software.
2.2.3. Drug release
Moxiﬂoxacin-loaded PLGA microparticles were embedded in CS–
PEG hydrogels for in vitro drug release testing. CS–NHS and PEG–
(NH2)6 were dissolved in PBS buffer and PBS/HEPES= 1:1 (v/v) buffer
to form 20% (w/v) solutions, respectively. PLGA microparticles of 2–
5mg were dissolved in 50μL PEG–(NH2)6 solution, and then mixed
with 50μL CS–NHS solution. The mixed solution was set quickly in a
cylinder capwith a diameter of 6mm for 10min to form a CS–PEG hy-
drogel. The PLGA microparticle-embedded CS–PEG gel was placed in
2mL PBS buffer (pH = 7.4) at 37 ◦C and 5% CO2. The release solutions
were sampled and refreshed at predetermined time points. The sam-
pling efﬁciencieswere used tomaintain the release solutions in a sink
condition. The sampled release solutions were analyzed by high per-
formance liquid chromatography (HPLC, Waters, Milford, MA). Three
types ofmoxiﬂoxacin-loaded PLGAmicroparticles prepared using dif-
ferent mixed solvents were studied. CS–PEG hydrogels with 5–10μg
moxiﬂoxacin HCl incorporated directly were also tested as controls.
Drug release experiments were run in duplicate for each condition
and average values were reported for each elution time point. Mox-
iﬂoxacin loading in PLGA particles was tested by dissolving 1–2mg
particles in 1mL 0.1M NaOH at 60 ◦C for 6h. The dissolved solution
was ﬁltered and examined using HPLC.
2.2.4. High performance liquid chromatography (HPLC)
Drug release solutions were characterized using a Waters HPLC
system equippedwith a pump, an autosampler, a UV/VIS detector set
at 293nm, and an analytical column (Waters, XTerra, RP18, 4.6mm
× 50mm, 5μm). The mobile phase consisted of 80:20 (v/v) HPLC
grade water (with 2% triethylamine and 2% phosphoric acid (50%))–
HPLC grade acetonitrile (with 10% water). The ﬂow rate was set at
1mL/min. The total run time of the HPLC analysis was 6min and
the retention time of moxiﬂoxacin HCl was 3.7min. The calibration
curve of the area-under-the-curve (AUC) vs. concentration of the drug
was determined using four standard solutions with concentrations
of 0.0μg/mL, 2.0μg/mL, 10.0μg/mL and 50.0μg/mL to reveal linear
relationships ( R2 = 0.9999).
2.2.5. Statistical ﬁtting
All drug release proﬁles were ﬁtted to Eq. (1) using SigmaPlot 11.0
software. Nonlinear regression was used with iterations of 100, step
size of 100, and tolerance of 0.0001. The coefﬁcient of determination,
R2, was determined for each ﬁtting curve.
3. Results and discussion
3.1. Microparticles fabrication
Moxiﬂoxacin-loaded PLGAmicroparticles were prepared using an
electrospraying technique. The electrospraying technique produces
small droplets from a polymer solution under high voltage. The small
droplets dry quickly in the air and become polymer particles before
being collected. The electrospraying processing conditionswere care-
fully optimized in terms of polymer solution preparation, voltage and
ﬂow rate applied, and particle collection method.
Three factors play an important role in preparation of the polymer
solution: the polymer selection, the solvent system, and the poly-
mer and drug concentrations. As shown in Fig. 1, moxiﬂoxacin has
a low molecular weight of 401 g/mol, and a relatively high aqueous
solubility compared to its minimum inhibitory concentration (MIC)
of 0.03μg/mL [2]. Hence, the well-studied biocompatible polymer,
PLGA (50/50), was selected in this study to extend the release of
moxiﬂoxacin by restricting the diffusion of the drug incorporated in
the polymer networks due to its hydrophobicity, biocompatibility,
and relatively high glass transition temperature [18,19].
The selection of the solvent formicroparticle fabrication is critical.
As noted above, the drug is hydrophilic, but the polymer chosen is
hydrophobic. The solvent requires (1) low boiling temperature, (2)
hydrophilicity to dissolve antibiotics, and (3) hydrophobicity to dis-
solve thepolymer. Therefore, a two-componentmixed solvent system
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Fig. 1. Molecular structure of moxiﬂoxacin.
Fig. 2. In vitro antibiotic release procedures: (a) moxiﬂoxacin (MXF)-loadedmicropar-
ticles were prepared from MXF–PLGA solution using electrospraying technique; (b)
these moxiﬂoxacin-loaded microparticles were collected by water-rinsing, vortexing,
centrifugation, and lyophilization; (c) moxiﬂoxacin particles were encapsulated into a
CS–PEG bioadhesive hydrogel; and (d) in vitro release of moxiﬂoxacin was performed
in PBS buffer (pH = 7.4).
of MeOH/DCMwas employed in this study. Themoxiﬂoxacin demon-
strates good solubility in methanol, but not in dichloromethane. In
contrast, the PLGA can dissolve easily in dichloromethane, but not in
methanol. Both moxiﬂoxacin and PLGA were able to dissolve in the
MeOH/DCM at various ratios of 10:90, 20:80, and 30:70 (v/v). Finally,
a low PLGA concentration of 1wt% in the mixed solvent solution was
applied to avoid particle tail formation during the electrospraying
process.
The voltage and ﬂow rate applied in this study were also care-
fully designed. During the electrospraying process (Fig. 2a), the poly-
mer solution ejected from the charged needle under high voltage can
demonstrate different geometrical forms [11]. When electric stresses
are balanced with the other forces existing in the liquid meniscus,
including surface tension force, gravity and viscosity force, the liquid
meniscus assumes Taylor cone geometry and breaks up into droplets
with a monodispersed size distribution [20,21]. This electrospraying
mode is called the cone-jet mode. If the forces on the liquid menis-
cus cannot maintain a balance under electrospraying conditions, the
liquidmeniscus becomes unstable and transforms to different shapes
other than the Taylor cone geometry [9,11]. In this work, we used a
ﬂow rate of 2mL/h to produce particles at a rate of approximately
20mg/h. At this ﬂow rate, the high voltage was adjusted carefully
so that the polymer solution meniscus ejected from the needle was
stable under the cone-jet mode. Speciﬁcally, for the three polymer
solutions using MeOH/DCM of 10:90, 20:80, and 30:70, we observed
a cone-jet mode at 11 kV, 12 kV, and 13kV, respectively. To avoid any
drug release burst, these electrosprayed microparticles were ﬁnally
collected and rinsed with water, and then lyophilized before use (Fig.
2b).
Fig. 3. SEM images (top) and particle size distributions (bottom) of moxiﬂoxacin-
loaded PLGA microparticles prepared using a mixed solvent system of MeOH/DCM
with ratios of (a) 10:90, (b) 20:80, and (c) 30:70. Scale: 5μm.
3.2. Microparticle characterization
The ratio of theMeOH/DCM solvent plays an important role in the
morphology of the particles collected. SEM images of moxiﬂoxacin-
loaded PLGA microparticles are shown in Fig. 3. These particles have
an average diameter of about 1μm with decreasing particle size ob-
served with increasing methanol content (Table 1). For each solvent
system, the PLGA microparticles were formed in two sets of parti-
cle sizes, with the smaller particles having diameters of less than
1μm. These smaller microparticles probably resulted from the break
up of larger microparticles because of coulombic ﬁssion. Coulombic
ﬁssion is a unique phenomenon of charged polymer droplets. It oc-
curs when the electrostatic repulsion force resulting from surface
charges increases beyond the surface tension force of droplets as a
result of evaporation [22]. As methanol content in the solvent system
of MeOH/DCM was increased from 10%, to 20%, and to 30% (v/v), the
percentage ofmicroparticles with diameters less than 1μm increased
from 29%, to 61%, and to 77%, respectively. Methanol (b.p. 65 ◦C) and
dichloromethane (b.p. 40 ◦C) have different evaporation rates, so the
mixed solvent with the higher methanol content dried more slowly
while the particles were ﬂying in the air before collected, and those
particles tended to break up more easily before collection. This may
also explain why the PLGA microparticles obtained at MeOH/DCM =
30:70 had rougher morphologies compared to those in the other two
solvent systems.
3.3. Moxiﬂoxacin release
In vitro release of moxiﬂoxacin from PLGA microparticles embed-
ded in CS–PEG bioadhesive hydrogels was investigated. These parti-
cles were collected and rinsed with water (Fig. 2b) to avoid any drug
burst release from the moxiﬂoxacin-loaded PLGAmicroparticles. The
remaining drug concentration in the microparticles was 0.21wt%,
0.16wt%, and 0.28wt% for MeOH/DCM of 10:90, 20:80, and 30:70,
respectively (Table 1).
Microparticles were encapsulated in a CS–PEG two-component
bioadhesive by in situ gelling (Fig. 2c). The structures of CS–NHS and
PEG–(NH2)6 are shown in Fig. 4a and b. Since the NHS functional
group is able to form amide bonds by reacting with any primary
amines, this bioadhesive can also integrate with human tissues, such
as those in theeye (Fig. 4c). Thedrug release tests of themicroparticle–
bioadhesive composite were performed in 2mL PBS buffer solution
(pH = 7.4) at 37 ◦C (Fig. 2d).
We observed slow release ofmoxiﬂoxacin using themixedMeOH/
DCM solvent. Fig. 5 illustrates the moxiﬂoxacin release proﬁles from
PLGA particles using MeOH/DCM = 30:70 embedded in CS–PEG hy-
drogel. The two hydrogels were loaded with moxiﬂoxacin of 4.5μg
and 9.3μg, respectively. Despite the large difference in loaded drug
amounts, the release proﬁles show a consistent fractional release (Fig.
Qiongyu Guo et al. / Results in Pharma Sciences 2 (2012) 66–71 69
Table 1




w/w) Voltage (kV) Particle Dia. (μm) t50 (d) t90 (d) β (d−1) R2 (%)
10:90 0.21 11 1.3±0.5 0.17 3.86 3.39 99.0
20:80 0.16 12 1.0±0.6 0.09 2.96 5.27 97.4
30:70 0.28 13 0.8±0.6 0.66 8.31 0.88 99.5
Ctrl N/A N/A N/A 0.03 0.14 43.27 99.2
Fig. 4. Schematic demonstration of molecular structures of (a) chondroitin sulfate
succinimidyl succinate (CS–NHS), (b) six arm polyethylene glycol amine (PEG–(NH2)6),
and (c) in situ gelling process of CS–PEG bioadhesive for encapsulating moxiﬂoxacin-
loaded PLGA microparticles at room temperature (RT).
Fig. 5. (a) Cumulative mass release and (b) fractional release of moxiﬂoxacin from
PLGA microparticles prepared using MeOH/DCM of 30:70 (average of two release ex-
periments).
5b).
The solvent system used to prepare the microparticles strongly
inﬂuenced the drug release rate (Fig. 6). The release speed of moxi-
ﬂoxacin using the mixed solvent of MeOH/DCM = 10:90 was slightly
slower than that using MeOH/DCM = 20:80. The time required for
50% drug release, called t50, was decreased from 4.1h forMeOH/DCM
= 10:90 to 2.2 h for MeOH/DCM = 20:80 (Table 1). Similarly, the
time required for 90% drug release, t90, was reduced from 3.9 days
for MeOH/DCM = 10:90 to 3.0 days for MeOH/DCM = 20:80. The
increased drug release rate with increasing content of methanol in
the solvent system is probably due to the decrease in microparticle
sizeswhen usingMeOH/DCM= 20:80 as comparedwithMeOH/DCM
= 10:90. The microparticles obtained from the MeOH/DCM = 30:70
solvent system had a much slower drug release rate than the other
two solvent concentrations (t50 = 15.8 h or 0.66 days, and t90 = 8.31
days), although these particles obtainedwere even smaller than those
in the other two conditions. This will be discussed later. Release of
moxiﬂoxacin was much more rapid when the drug molecules were
incorporated directly into the hydrogel (t50 = 0.7 h or 0.03 days, and
t90 = 3.4 h or 0.14 days).
All of the release curves in Fig. 6 were well ﬁtted by drug release
Fig. 6. Moxiﬂoxacin release proﬁles for 12 days (a) from PLGA microparticles embed-
ded in CS–PEG hydrogel prepared usingMeOH/DCMof 10:90, 20:80, and 30:70, aswell
as a control with the antibiotics loaded directly into the CS–PEG hydrogel. (b) Details
of the drug release proﬁles for Day 1.
approximation equation based on Fickian diffusional transport [19],





where f(t) is deﬁned as the ratio of the absolute cumulative mass
of drug released at time, t, to that at inﬁnite time, and β is the ini-
tial diffusion rate constant. As shown in Table 1, the initial diffusion
rate constant was decreased from 5.27 d−1 for MeOH/DCM = 20:80,
to 3.39 d−1 for MeOH/DCM = 10:90, and to 0.88 d−1 for MeOH/
DCM= 30:70. All initial diffusion rate constants were greatly reduced
compared to the control with the drug incorporated in the hydrogel
directly (i.e. 43.27 d−1). As expected, the initial diffusion rate constant
showed an opposite relationship as t50.
The daily release rate of moxiﬂoxacin decreased exponentially
with time (Fig. 7). As expected, the slope of the daily release rate
vs. time in log—log scale was smaller for MeOH/DCM = 30:70 than
those for MeOH/DCM of 10:90 and 20:80. The two daily release rate
slopeswere close for two cases ofMeOH/DCM= 30:70 solvent loaded
with different amounts ofmoxiﬂoxacin,which indicates that the daily
release rate at each time point can be easily scaled up by adding
more drug-loaded microparticles. All of these conditions show an
effective release over 10 days with the release concentration higher
than the minimum inhibitory concentration (MIC, 0.03μg/mL) [2].
As little as 4.5μg of moxiﬂoxacin loaded in the microparticles made
with MeOH/DCM = 30:70 was sufﬁcient to achieve a drug release
that was higher than the MIC for more than 10 days. This amount
of moxiﬂoxacin in the microparticles is only 1.8% of the drug in one
drop of moxiﬂoxacin eyedrops (VIGAMOX
®
Ophthalmic Solution,
moxiﬂoxacin HCl 0.5%, 5mg/mL, Alcon Laboratories, Inc., Fort Worth,
TX). Currently, moxiﬂoxacin eyedrops are applied 3 times a day for
7 days to the surface of the affected eye. The controlled drug system
using moxiﬂoxacin-loaded PLGA particles applied in situ by CS–PEG
bioadhesive is promising for a one-time applicationwithmuchhigher
efﬁcacy than an eye drop formulation.
3.4. Microparticle formation and release mechanism
The unique solvent system applied in the electrospraying solu-
tion strongly inﬂuenced the drug release behavior. As noted above,
moxiﬂoxacin is comparatively hydrophilic and has good solubility in
methanol, but not in dichloromethane. In contrast, the PLGA poly-
mer is hydrophobic and can dissolve easily in dichloromethane, but
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Fig. 7. Moxiﬂoxacin release rates from PLGA microparticles prepared using MeOH/
DCM of 10:90 and 30:70. The total drug loading mass is indicated. The minimum
inhibitory concentration (MIC) ofmoxiﬂoxacinwas 0.03μg/mL, as shownby thedashed
reference line.
Fig. 8. Microparticle formation mechanism during electrospraying processing. During
evaporation of a primary electrosprayed droplet, the mixed solvent system of MeOH/
DCM provides a driving force for the moxiﬂoxacin molecules to diffuse into the center
of the polymeric particles.
not in methanol. Since methanol has a much higher boiling tem-
perature than dichloromethane, methanol dries more slowly than
dichloromethane and shows greater accumulation in the center of
the polymer particle. This solvent distribution likely provides a driv-
ing force for the drug molecules to diffuse into the center of the
particles, leading to a gradient of the drug concentration, and thus a
decrease in the drug release rate from the particles (Fig. 8). This may
explain why, in the three tested solvent systems, the MeOH/DCM =
30:70 solvent, with the highest content of methanol, produced parti-
cles with longest duration drug release, despite having the smallest
particle size.
This phenomenon may also explain why a bowl-like morphology
was obtained when using the MeOH/DCM = 10:90 and 20:80 mixed
solvents. During the drying process, the solvent at the edge of the
electrosprayed droplets evaporated ﬁrst and formed a polymer shell.
If the particles are collected before they are completely dry, the high
impact of the particles when reaching the collector could force the
particles to form in a bowl shape.
4. Conclusion
We investigated controlled delivery of moxiﬂoxacin from poly-
mer microparticles encapsulated in a CS–PEG two-component bioad-
hesive hydrogel for ocular treatments. Moxiﬂoxacin-loaded PLGA
microparticles were successfully prepared using an electrospraying
technique under optimized conditions for polymer solution prepa-
ration, voltage and ﬂow rate applied, and particle collection method.
We achieved extended release ofmoxiﬂoxacin using a series ofmixed
MeOH/DCM solvents. All release curves follow a Fickian diffusional
release pattern. We found that the mixed solvent system may pro-
vide a driving force for the moxiﬂoxacin molecules to diffuse into the
center of the polymer particles when prepared by electrospraying
processing. This would likely lead to a gradient of drug concentra-
tions in the particles and, thus, a decrease in the drug release rate
from the particles. This electrospraying technique using the unique
solvent systems may be applicable for achieving controlled release of
other types of small molecule hydrophilic drugs, which, using con-
ventional techniques, has been a challenge.
Currently, ophthalmic release of the antibiotics between 7 and 14
days is suggested to increase bacterial eradication and to avoid possi-
ble adverse events [23]. The controlled release of moxiﬂoxacin for 10
days, as achieved in this study, may lead to development of a mox-
iﬂoxacin in situ gelling microparticles–bioadhesive delivery system
that may be applied in one dose and will have a much higher efﬁ-
cacy than conventional eyedrop formulations have. Furthermore, the
microparticle–bioadhesive delivery system in this study also provides
a template for controlled release of drugs other thanmoxiﬂoxacin and
for localized release in human tissues other than those in the eye. Ad-
ditionally, this delivery system may be particularly helpful for farm,
lab and pet animals when confronting with dosage difﬁculties.
Acknowledgments
Weacknowledge theArthritis FoundationPostdoctoral Fellowship
Award (QG) and the Congressionally Directed Medical Research Pro-
gram under the U.S. Army Medical Research and Materiel Command
(Contract no. W81XWH-09-2-0173, Program Manager Dr. Dwayne
Taliaferro).
References
[1] Culley C.M., Lacy M.K., Klutman N., Edwards B. Moxiﬂoxacin: clinical efﬁcacy
and safety. American Journal of Health-System Pharmacy. 2001;58:379–388.
[2] SpecialeA.,MusumeciR., BlandinoG.,Milazzo I., CaccamoF.,NicolettiG.Minimal
inhibitory concentrations and time-kill determination of moxiﬂoxacin against
aerobic and anaerobic isolates. International Journal of Antimicrobial Agents.
2002;19:111–118.
[3] MillerD. Reviewofmoxiﬂoxacinhydrochloride ophthalmic solution in the treat-
ment of bacterial eye infections. Clinical Ophthalmology. 2008;2:77–91.
[4] Kisich K.O., Gelperina S., Higgins M.P., Wilson S., Shipulo E., Oganesyan E. et al.
Encapsulation of moxiﬂoxacin within poly(butyl cyanoacrylate) nanoparticles
enhances efﬁcacy against intracellularMycobacterium tuberculosis. International
Journal of Pharmaceutics. 2007;345:154–162.
[5] Ventura C.A., Tommasini S., Crupi E., Giannone I., Cardile V., Musumeci T. et al.
Chitosan microspheres for intrapulmonary administration of moxiﬂoxacin: in-
teraction with biomembranemodels and in vitro permeation studies. European
Journal of Pharmaceutics and Biopharmaceutics. 2008;68:235–244.
[6] Cohen S., Lobel E., Trevgoda A., Peled Y. A novel in situ-forming ophthalmic
drug delivery system from alginates undergoing gelation in the eye. Journal of
Controlled Release. 1997;44:201–208.
[7] Shastri D.H., Prajapati S.T., L.D.Patel. Design and development of thermore-
versible ophthalmic in situ hydrogel ofmoxiﬂoxacinHCl. Current DrugDelivery.
2010;7:238-243.
[8] Chee S.P. Moxiﬂoxacin punctum plug for sustained drug delivery. Journal of
Ocular Pharmacology and Therapeutics. 2012;28:340–349.
[9] Jaworek A., Sobczyk A.T. Electrospraying route to nanotechnology: an overview.
Journal of Electrostatics. 2008;66:197–219.
[10] Chakraborty S., Liao I.C., Adler A., Leong K.W. Electrohydrodynamics:a facile
technique to fabricate drug delivery systems. Advanced Drug Delivery Reviews.
2009;61:1043–1054.
[11] Jaworek A., Krupa A. Classiﬁcation of the modes of EHD spraying. Journal of
Aerosol Science. 1999;30:873–893.
[12] Rosca I.D., Watari F., Uo M. Microparticle formation and its mechanism in sin-
gle and double emulsion solvent evaporation. Journal of Controlled Release.
2004;99:271–280.
[13] Khoee S., YaghoobianM. An investigation into the role of surfactants in control-
ling particle size of polymeric nanocapsules containing penicillin-G in double
emulsion. European Journal of Medicinal Chemistry. 2009;44:2392–2399.
[14] Wang D.A., Varghese S., Sharma B., Strehin I., Fermanian S., Gorham J. et al. Mul-
tifunctional chondroitin sulphate for cartilage tissue-biomaterial integration.
Nature Materials. 2007;6:385–392.
[15] Strehin I., Ambrose W.M., Schein O., Salahuddin A., Elisseeff J. Synthesis and
characterization of a chondroitin sulfate-polyethylene glycol corneal adhesive.
Journal of Cataractand Refractive Surgery. 2009;35:567–576.
[16] Strehin I., Nahas Z., Arora K., Nguyen T., Elisseeff J. A versatile pH sensitive chon-
droitin sulfate-PEG tissue adhesive and hydrogel. Biomaterials. 2010;31:2788–
2797.
[17] Peppas N.A., Sahlin J.J. Hydrogels as mucoadhesive and bioadhesive materials:a
review. Biomaterials. 1996;17:1553–1561.
[18] Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA
microspheres. Advanced Drug Delivery Reviews. 1997;28:5–24.
Qiongyu Guo et al. / Results in Pharma Sciences 2 (2012) 66–71 71
[19] Guo Q., Knight P.T., Mather P.T. Tailored drug release from biodegradable
stent coatings based on hybrid polyurethanes. Journal of Controlled Release.
2009;137:224–233.
[20] Taylor G. Disintegration of water drops in an electric ﬁeld. Proceedings of the
Royal Society of London, Series A. 1964;280:383–397.
[21] Meesters G.M.H., Vercoulen P.H.W., Marijnissen J.C.M., Scarlett B. Generation
of micron-sized droplets from the Taylor cone. Journal of Aerosol Science.
1992;23:37–49.
[22] Duft D., Achtzehn T., Muller R., Huber B.A., Leisner T. Coulomb ﬁssion: Rayleigh
jets from levitated microdroplets. Nature. 2003;421:128.
[23] Miehlke S., Krasz S., Schneider-Brachert W., Kuhlisch E., Berning M., Madisch A.
et al. Randomized trial on 14 versus 7 days of esomeprazole, moxiﬂoxacin, and
amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
Helicobacter. 2011;16:420–426.
